Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
2023年9月13日 - 5:00AM
ビジネスワイヤ(英語)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced the speakers for its
upcoming Investor & Analyst Event on Tuesday, September 19 from
9:00 a.m. to 1:00 p.m. Eastern Time in New York.
The Investor & Analyst Event will feature presentations by
Marinus’ leaders who will discuss the Company’s late-stage clinical
pipeline programs, commercial planning activities, second
generation product development and business outlook. In addition,
key opinion leaders will discuss their clinical experience treating
patients with status epilepticus and tuberous sclerosis complex,
the burden of illness, cost of care to the health system, and a
host of other topics.
Marinus Speakers:
- Scott Braunstein, M.D., Chairman of the Board & Chief
Executive Officer
- Steven E. Pfanstiel, Chief Financial Officer and Chief
Operating Officer
- Joseph Hulihan, M.D., Chief Medical Officer
- Christy Shafer, Chief Commercial Officer
- Alex Aimetti, Ph.D., Chief Scientific Officer
- Sonya Weigle, Senior Vice President, IR, HR & Corporate
Affairs
- Lisa Lejuwaan, Senior Vice President, Business Unit Lead, Rare
Genetic Epilepsy
- Henri Vaitkevicius, M.D., Vice President, Clinical
Development
- Kristin Rudisill, Vice President Acute Care
Key Opinion Leader (KOL) Speakers:
- Dr. Rajat Dhar, M.D., Professor of Neurology in the Section of
Neurocritical care at Washington University School of Medicine in
St. Louis, Attending Physician in the Neurology/Neurosurgery
Intensive Care Unit at Barnes-Jewish Hospital
- Dr. Fawad A. Khan, M.D., Director, The International Center for
Epilepsy at Ochsner Neurosciences Institute; Associate Professor,
Ochsner Clinical School/University of Queensland
- Dr. Mary Kay Koenig, M.D., Director of the Center for Treatment
of Pediatric Neurodegenerative Disease (CTPND), Director of
Research for the Division of Child & Adolescent Neurology at
the University of Texas McGovern Medical School
In-person attendance is open to invited research analysts and
institutional investors. All others are invited to watch the live
video webcast. Live questions will be taken by in-person guests,
and virtual participants may submit questions through the webcast
platform.
To register for the video webcast, please visit the Investor
Relations section of the Company's website at
https://ir.marinuspharma.com/events-and-presentations/. A replay of
the webcast will be archived on the Investor Relations section of
the Company's website following the event.
Featured KOL Speaker Biographies:
Dr. Raj Dhar is a Professor of Neurology in the Section of
Neurocritical care at Washington University in St. Louis and an
Attending Physician in the Neurology/Neurosurgery Intensive Care
Unit at Barnes-Jewish Hospital. He specializes in acute brain
injury including stroke, subarachnoid hemorrhage, and head trauma.
He completed his neurology residency at the University of Western
Ontario and his fellowship in Neurological Critical Care at
Washington University School of Medicine. He is certified by the
American Board of Psychiatry and Neurology in Vascular Neurology
and from the United Council of Neurological Subspecialties in
Neurocritical Care. He has served as Chair of the Scientific
Committee for the annual meeting of the Neurocritical Care Society
and Chair of the Organ Donation Research Council. Dr. Dhar is an
investigator for the RAISE clinical trial.
Dr. Fawad A. Khan is a board certified neurologist at Ochsner
Medical Center in New Orleans. He specializes in epilepsy and
seizure disorders, headache care and dizziness. He completed his
residency in adult neurology at the University of North Carolina
Hospitals in Chapel Hill, North Carolina. Dr. Khan completed a
fellowship in clinical neurophysiology and epilepsy at the
University of Michigan Hospitals in Ann Arbor, Michigan. He is the
Section Head of The International Center for Epilepsy at Ochsner
and the Neurodiagnostics Service Line at Ochsner Health. He is a
fellow of the American Epilepsy Society and the American Clinical
Neurophysiology Society. Dr. Khan is a clinician-researcher and is
passionate about exploring innovative solutions to improve clinical
care. Dr. Khan is an investigator for the RAISE clinical trial.
Dr. Mary Kay Koenig serves as the Director of the Center for the
Treatment of Pediatric Neurodegenerative Disease (CTPND) and
Director of Research for the Division of Child & Adolescent
Neurology at the University of Texas McGovern Medical School. Dr.
Koenig attended the University of Texas in Austin where she
received a Bachelor of Arts in Biochemistry. Following
undergraduate school, Dr. Koenig received a Masters of Science in
Microbiology at Southwest Texas State University followed by her
Medical Doctorate at St. George’s School of Medicine. After medical
school, Dr. Koenig completed a pediatrics residency at the
University of Texas Medical Branch in Galveston and a fellowship in
Child and Adolescent Neurology at The University of Texas Medical
School. Upon completion of her fellowship, she joined the faculty
and is now a tenured professor. She has served as the director for
the UT Mitochondrial Center of Excellence since 2007, the
co-Director for the UT Memorial Hermann Tuberous Sclerosis Clinic
since 2007, and the Leigh Syndrome clinic director since 2013. Dr.
Koenig strives to provide excellent clinic care and advance
research for children afflicted with genetic neurodegenerative
disease. She also works to mentor and educate junior faculty,
fellows, residents, and medical students in the art of medicine and
clinical research. Dr. Koenig is an investigator for the TrustTSC
clinical trial.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company first introduced FDA-approved prescription
medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in
2022 and continues to invest in the potential of ganaxolone in IV
and oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912087838/en/
Investors Jim DeNike Senior
Director, Investor Relations Marinus Pharmaceuticals, Inc.
jdenike@marinuspharma.com
Media Molly Cameron Director,
Corporate Communications & Investor Relations Marinus
Pharmaceuticals, Inc. mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 4 2024 まで 5 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 5 2023 まで 5 2024